Investigators report findings from a phase 3 trial demonstrating that transdermal estradiol patches were as effective as luteinizing hormone-releasing hormone agonists.

US endocrinologists are favoring antithyroid drugs over radioactive iodine in initial Graves’ disease treatment, and new ...

Bayer AG BAYRY reported third-quarter 2024 core earnings of 7 cents per American Depositary Receipt (ADR), which missed the ...

In addition to the several large insurance partnerships with Flo, our Yale and August businesses made progress with some key customers, including integrations with ADT, ecobee and Airbnb ... and ...

Theragent Inc., a comprehensive CDMO focused on advancing next-generation cell-based therapies, has announced a significant milestone for both Theragent and its sponsor client, CellVax ...

We conducted a phase 3, international, open-label, randomized ... higher-risk disease receiving androgen-deprivation therapy (ADT). Here, we report the primary analysis of PACE-B, which assessed ...

Q3 2024 Earnings Call Transcript November 6, 2024 Fortune Brands Innovations, Inc. beats earnings expectations. Reported EPS ...

ADT Medical Alert doesn’t offer a free trial period like many other providers. However, if you decide to cancel your service, they will reimburse you for any unused days in the billing cycle. They ...

In total, the international, open-label, randomized, controlled trial enrolled 874 patients ... patients needed to have a Gleason score of 3+4 or less and a PSA level of no more than 20 ng/mL. ADT was ...

ARASEC is a US-based, phase 2, open-label, single-arm study with an external control arm. Patients with mHSPC will receive darolutamide 600 mg twice daily plus ADT. The control arm for ARASEC will be ...